[Plant-made pharmaceuticals].
Antibodies have long been recognized for their diagnostic and therapeutic potential. The rapidly increasing number of monoclonal antibodies approved for immunotherapy have paved the way to an even greater demand for antibody molecules. In order to satisfy this growing demand, alternative systems based on transgenic organisms are actively explored to increase the production capacity. In this paper, we will focus on transgenic plants as a promising large scale production and processing system.
Faye
L
L
CNRS UMR 6037-IFRMP23-Université de Rouen, F76821 Mont St Aignan, France.
Lerouge
P
P
Gomord
V
V
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000235:genetics; D006031:Glycosylation; D006801:Humans; D010944:Plants / Q000235:genetics / Q000378:metabolism*; D030821:Plants, Genetically Modified / Q000235:genetics / Q000378:metabolism*; D011994:Recombinant Proteins / Q000096:biosynthesis
D000911:Antibodies, Monoclonal; D011994:Recombinant Proteins